Zoetis (ZTS) Gains from Investment Securities (2012 - 2026)
Zoetis (ZTS) reported Gains from Investment Securities of $50.0 million for Q1 2026, up 5100.0% year-over-year from $961538.5 in Q1 2025, and down 93.03% quarter-over-quarter from $717.0 million in Q4 2025.
Zoetis (ZTS) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Gains from Investment Securities data on file, last reported at $50.0 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $50.0 million, up 5100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $766.0 million (changed N/A YoY), and the FY2025 annual result was $715.0 million, up 35650.0% from the prior year.
- Gains from Investment Securities fell to $50.0 million in Q1 2026 per ZTS's latest filing, from $717.0 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $717.0 million in Q4 2025 and troughed at -$479.0 million in Q3 2024.
- A 5-year average of $47.6 million and a median of $2.0 million in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2026: Gains from Investment Securities plunged 9300.0% in 2023, then soared 5100.0% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at -$46.0 million in 2022, then jumped by 91.3% to -$4.0 million in 2023, then slumped by 11875.0% to -$479.0 million in 2024, then surged by 249.69% to $717.0 million in 2025, then sank by 93.03% to $50.0 million in 2026.
- Business Quant data shows ZTS's Gains from Investment Securities at $50.0 million in Q1 2026, $717.0 million in Q4 2025, and -$4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.00 Mn |
| Mar 31, 2026 | 50.00 Mn |
| Dec 31, 2025 | 717.00 Mn |
| Dec 31, 2025 | 717.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | -1.00 Mn |
| Mar 31, 2025 | -1.00 Mn |
| Sep 30, 2024 | -479.00 Mn |
| Sep 30, 2024 | -479.00 Mn |
| Jun 30, 2024 | 480.00 Mn |
| Jun 30, 2024 | 480.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | -4.00 Mn |
| Dec 31, 2023 | -4.00 Mn |
| Sep 30, 2023 | -460.00 Mn |
| Sep 30, 2023 | -460.00 Mn |